tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Glaukos, Citing Long-Term iDose Opportunity and Upcoming Epioxa-Driven Growth
PremiumRatingsAnalyst Reiterates Buy on Glaukos, Citing Long-Term iDose Opportunity and Upcoming Epioxa-Driven Growth
21d ago
Glaukos pullback due to concerns about iDose LCD, says William Blair
Premium
The Fly
Glaukos pullback due to concerns about iDose LCD, says William Blair
28d ago
Steven Lichtman Reiterates Buy on Glaukos, Citing Manageable Coverage Risk and Robust Multiyear iDose Growth Outlook
Premium
Ratings
Steven Lichtman Reiterates Buy on Glaukos, Citing Manageable Coverage Risk and Robust Multiyear iDose Growth Outlook
28d ago
Glaukos Corp. Earnings Call Signals Growth Momentum
PremiumCompany AnnouncementsGlaukos Corp. Earnings Call Signals Growth Momentum
2M ago
Glaukos price target raised to $153 from $134 at Goldman Sachs
Premium
The Fly
Glaukos price target raised to $153 from $134 at Goldman Sachs
2M ago
Glaukos price target raised to $170 from $160 at Stifel
Premium
The Fly
Glaukos price target raised to $170 from $160 at Stifel
2M ago
Glaukos Reaffirmed as Buy on Strong Q1 Beat, Raised 2026 Revenue Outlook, and Billion-Dollar Peak Potential for iDose and Epioxa
PremiumRatingsGlaukos Reaffirmed as Buy on Strong Q1 Beat, Raised 2026 Revenue Outlook, and Billion-Dollar Peak Potential for iDose and Epioxa
2M ago
Glaukos reports Q1 EPS (18c), consensus (28c)
Premium
The Fly
Glaukos reports Q1 EPS (18c), consensus (28c)
2M ago
Glaukos sees FY26 revenue $620M-$635M, consensus $614.4M
Premium
The Fly
Glaukos sees FY26 revenue $620M-$635M, consensus $614.4M
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100